This past financial year has been full of significant milestones and continued growth for us at Memphasys. From launching our Felix™ System in new markets to expanding our partnerships globally, we’ve been laser-focused on our mission to advance reproductive technology for both humans and animals.
One of our proudest achievements this year has been the successful commercialisation of the Felix™ System in Japan, with more than 500 cartridges already supplied. Felix™ is an automated sperm separation system designed for IVF clinics, allowing for a quick, gentle, and precise isolation of high-quality sperm in just seven minutes. With our exclusive distribution agreement with Vitrolife Japan KK, we’ve gained access to one of the largest IVF markets in the world. And this is only the beginning.
The Japanese market has responded positively, and we’ve now expanded our reach to New Zealand and Canada with similar distribution deals. While we’ve made strong headway in these “early access markets,” we are already preparing for the broader launch of the Felix™ System in highly regulated regions like Australia, the United States, and the European Union.
Beyond Felix™, we’ve also been working hard on other groundbreaking technologies. The RoXsta™ system, which measures oxidative stress in reproductive cells, is on track to make a real impact in human fertility clinics and potentially the livestock industry as well. This diagnostic device will allow us to address oxidative stress, a known cause of infertility, with a quick, five-minute test—offering an affordable and accessible solution for both humans and animals.
As we reflect on this year’s progress, we’ve also streamlined our internal operations, ensuring our resources are aligned for the next stage of growth. This includes a successful relocation of our offices and significant savings in operational costs, which are being reinvested in research, development, and commercialisation efforts.
Looking ahead, the upcoming year promises even more excitement. We’re eagerly anticipating the results from our larger clinical trials for Felix™, which will pave the way for even broader market adoption. Our journey doesn’t stop here; we’re committed to pushing the boundaries of what’s possible in reproductive technology.
Here’s to another year of breakthroughs!